title: Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.
abstract: We previously reported that fluorouracil (5FU) accumulation and metabolism in human livers and tumors can be studied by in vivo nuclear magnetic resonance spectroscopy (NMRS). We have extended these observations by evaluating the pharmacokinetics of 5FU in the tumors of 11 patients with carcinoma of the breast, colon, endometrium, cervix, and kidney, using 19F-NMRS in a 1.5 Magnetom (Siemens Medical Systems, Cerrito, CA) magnetic resonance imaging unit (MRI). These NMRS measurements detected a long-lived tumor pool of 5FU in six of 11 tumors in our patients including carcinomas in the pelvis, breast, lung, and liver. The half-life (T1/2) of this tumor pool of "trapped" 5FU was 0.33 to 1.3 hours (20 to 78 minutes), much longer than the T1/2 of 5FU in blood (5 to 15 minutes). Neither the anabolites of 5FU (fluorinated nucleosides, nucleotides, 5FU-RNA, or 5FU-thymidylate synthase) nor the catabolites (eg, fluorobetaalanine [FBAL]) were detectable by 19F NMRS. Patient response to chemotherapy appeared to correlate with the extent of trapping of free 5FU in the human tumors: in the seven patients receiving 5FU, or 5FU or FUdR plus leucovorin, four of four patients whose tumors trapped 5FU responded to fluorinated pyrimidine chemotherapy, whereas three patients in whom there was a failure to detect tumor trapping were resistant to 5FU. We conclude that NMRS is clinically feasible, and enables investigators to study 5FU pharmacokinetics and metabolism in tumors in vivo. 19F-NMRS of 5FU allows for in vivo evaluation of 5FU metabolic modulation and might be able to guide therapeutic decisions.
authors.affiliation: Los Angeles Oncologic Institute, Wilshire Oncology Medical Group, CA.
authors.forename: C A
authors.initials: CA
authors.lastname: Presant
authors.forename: W
authors.initials: W
authors.lastname: Wolf
authors.forename: M J
authors.initials: MJ
authors.lastname: Albright
authors.forename: K L
authors.initials: KL
authors.lastname: Servis
authors.forename: R
authors.initials: R
authors.lastname: Ring
authors.forename: D
authors.initials: D
authors.lastname: Atkinson
authors.forename: R L
authors.initials: RL
authors.lastname: Ong
authors.forename: C
authors.initials: C
authors.lastname: Wiseman
authors.forename: M
authors.initials: M
authors.lastname: King
authors.forename: D
authors.initials: D
authors.lastname: Blayney
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005461:Fluorine; D005472:Fluorouracil / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D005461:Fluorine; D002955:Leucovorin; D005472:Fluorouracil